Futura Medical Plc (FAMDF) 0.2800 $FAMDF
Cellulite Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Endo International, Futura Medical, Nestle - Research and Markets
BusinessWire - Wed May 04, 4:03AM CDT
Research and Markets has announced the addition of the "Cellulite Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
Cellulite Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/65jxhb/cellulite_global) has announced the addition of the "Cellulite Global Clinical Trials Review, H1, 2015" report to their offering. This report provides an overview of Cellulite clinical trials scenario. This report provides top line data relating to the clinical trials on Cellulite. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - ALIO MEDICA - Endo International - Futura Medical - Halozyme Therapeutics - L. Manetti H. Roberts & C. - Nutrasource Diagnostics - Premier Research - Royal DSM - Venus Remedies For more information visit http://www.researchandmarkets.com/research/65...ite_global
Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.50 (-0.01), APRI: 0.42 (-0.03), ACOR: 28.26 (-1.44)
New Generation Topical Pain Relief From Futura Medical
PR Newswire Europe - Wed Jul 15, 4:01AM CDT
LONDON, July 15, 2015 /PRNewswire/ --
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.50 (-0.01), APRI: 0.42 (-0.03)
Global Premature Ejaculation Market 2014-2018: Key Vendors are Absorption, Furiex, Innovus and Plethora
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thdrgd/global_premature) has announced the addition of the "Global Premature Ejaculation Market 2014-2018" report to their offering. Premature ejaculation is a common sexual dysfunction in men, which is characterized by early discharge of semen. Premature ejaculation can be diagnosed through IELT, which is the average time taken by a man to ejaculate during sexual intercourse. There are two types of premature ejaculation: Primary premature ejaculation and secondary premature ejaculation. The analysts forecast the Global Premature Ejaculation market to grow at a CAGR of 10.20 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Premature Ejaculation market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of premature ejaculation that are available in the market. The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Premature Ejaculation market. In addition, the report discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors and the market at large. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview and Management 08. Market Landscape 09. Market Segmentation by Route of Administration 10. Market Segmentation by Dosage Form 11. Market Segmentation by Mechanism of Action 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Absorption - Furiex - Innovus - Plethora - Bayer - Dong-A ST - Eli Lilly - Emcure - Endo - Futura Medical - GlaxoSmithKline - Medisyn - Menarini - NeuroHealing - Pfizer - Shionogi - Symyoo - Vectura - Vyrix For more information visit http://www.researchandmarkets.com/research/th..._premature
LLY: 74.70 (-0.14), GSK: 42.70 (-0.15)
Cellulite Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Endo International, Futura Medical, Nestle - Research and Markets
BusinessWire - Wed May 04, 4:03AM CDT
Research and Markets has announced the addition of the "Cellulite Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
Cellulite Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/65jxhb/cellulite_global) has announced the addition of the "Cellulite Global Clinical Trials Review, H1, 2015" report to their offering. This report provides an overview of Cellulite clinical trials scenario. This report provides top line data relating to the clinical trials on Cellulite. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - ALIO MEDICA - Endo International - Futura Medical - Halozyme Therapeutics - L. Manetti H. Roberts & C. - Nutrasource Diagnostics - Premier Research - Royal DSM - Venus Remedies For more information visit http://www.researchandmarkets.com/research/65...ite_global
Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.50 (-0.01), APRI: 0.42 (-0.03), ACOR: 28.26 (-1.44)
New Generation Topical Pain Relief From Futura Medical
PR Newswire Europe - Wed Jul 15, 4:01AM CDT
LONDON, July 15, 2015 /PRNewswire/ --
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.50 (-0.01), APRI: 0.42 (-0.03)
Global Premature Ejaculation Market 2014-2018: Key Vendors are Absorption, Furiex, Innovus and Plethora
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thdrgd/global_premature) has announced the addition of the "Global Premature Ejaculation Market 2014-2018" report to their offering. Premature ejaculation is a common sexual dysfunction in men, which is characterized by early discharge of semen. Premature ejaculation can be diagnosed through IELT, which is the average time taken by a man to ejaculate during sexual intercourse. There are two types of premature ejaculation: Primary premature ejaculation and secondary premature ejaculation. The analysts forecast the Global Premature Ejaculation market to grow at a CAGR of 10.20 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Premature Ejaculation market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of premature ejaculation that are available in the market. The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Premature Ejaculation market. In addition, the report discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors and the market at large. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview and Management 08. Market Landscape 09. Market Segmentation by Route of Administration 10. Market Segmentation by Dosage Form 11. Market Segmentation by Mechanism of Action 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Absorption - Furiex - Innovus - Plethora - Bayer - Dong-A ST - Eli Lilly - Emcure - Endo - Futura Medical - GlaxoSmithKline - Medisyn - Menarini - NeuroHealing - Pfizer - Shionogi - Symyoo - Vectura - Vyrix For more information visit http://www.researchandmarkets.com/research/th..._premature
LLY: 74.70 (-0.14), GSK: 42.70 (-0.15)
